Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Advanced breast cancer
Asia
HER2-low
Interstitial lung disease
Trastuzumab deruxtecan
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
received:
29
03
2024
accepted:
25
05
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-human epidermal growth factor 2 (HER2) antibody-drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated a statistically significant improvement in progression-free survival (PFS) and overall survival (OS), with manageable safety compared with treatment of physician's choice (TPC) in patients with HER2-low metastatic breast cancer (mBC) who had received 1-2 prior lines of chemotherapy. This subgroup analysis examined the efficacy and safety of T-DXd versus TPC in 213 patients from Asian countries and regions who were enrolled in the DESTINY-Breast04 trial and randomized to T-DXd (n = 147) or TPC (n = 66). Median PFS with T-DXd and TPC was 10.9 and 5.3 months, respectively, in Asian patients with hormone receptor-positive mBC, and 10.9 and 4.6 months, respectively, in the overall Asian population. In both populations, median OS was not reached with T-DXd and was 19.9 months with TPC. The objective response rate was higher with T-DXd versus TPC in all Asian patients. Median treatment duration was 8.4 months with T-DXd and 3.5 months with TPC. The most common grade ≥ 3 drug-related treatment-emergent adverse events in Asian patients treated with T-DXd were neutropenia (16.3%), anemia (12.9%), and leukopenia (11.6%); the incidences of neutropenia and leukopenia were higher with TPC versus T-DXd. Adjudicated drug-related interstitial lung disease or pneumonitis with T-DXd was 14.3%; the majority of events were grade 1-2. T-DXd demonstrated clinically meaningful survival benefits versus TPC in Asian HER2-low mBC patients, regardless of hormone receptor status, with no new safety signals. ClinicalTrials.gov, NCT03734029.
Sections du résumé
BACKGROUND
BACKGROUND
In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-human epidermal growth factor 2 (HER2) antibody-drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated a statistically significant improvement in progression-free survival (PFS) and overall survival (OS), with manageable safety compared with treatment of physician's choice (TPC) in patients with HER2-low metastatic breast cancer (mBC) who had received 1-2 prior lines of chemotherapy.
METHODS
METHODS
This subgroup analysis examined the efficacy and safety of T-DXd versus TPC in 213 patients from Asian countries and regions who were enrolled in the DESTINY-Breast04 trial and randomized to T-DXd (n = 147) or TPC (n = 66).
RESULTS
RESULTS
Median PFS with T-DXd and TPC was 10.9 and 5.3 months, respectively, in Asian patients with hormone receptor-positive mBC, and 10.9 and 4.6 months, respectively, in the overall Asian population. In both populations, median OS was not reached with T-DXd and was 19.9 months with TPC. The objective response rate was higher with T-DXd versus TPC in all Asian patients. Median treatment duration was 8.4 months with T-DXd and 3.5 months with TPC. The most common grade ≥ 3 drug-related treatment-emergent adverse events in Asian patients treated with T-DXd were neutropenia (16.3%), anemia (12.9%), and leukopenia (11.6%); the incidences of neutropenia and leukopenia were higher with TPC versus T-DXd. Adjudicated drug-related interstitial lung disease or pneumonitis with T-DXd was 14.3%; the majority of events were grade 1-2.
CONCLUSIONS
CONCLUSIONS
T-DXd demonstrated clinically meaningful survival benefits versus TPC in Asian HER2-low mBC patients, regardless of hormone receptor status, with no new safety signals.
CLINICAL TRIAL REGISTRATION NUMBER
BACKGROUND
ClinicalTrials.gov, NCT03734029.
Identifiants
pubmed: 38884900
doi: 10.1007/s12282-024-01600-7
pii: 10.1007/s12282-024-01600-7
doi:
Banques de données
ClinicalTrials.gov
['NCT03734029']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1. https://doi.org/10.1038/s41523-020-00208-2 .
doi: 10.1038/s41523-020-00208-2
pubmed: 33397968
pmcid: 7782714
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–62. https://doi.org/10.1200/jco.19.02488 .
doi: 10.1200/jco.19.02488
pubmed: 32330069
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open. 2023;8(4): 101615. https://doi.org/10.1016/j.esmoop.2023.101615 .
doi: 10.1016/j.esmoop.2023.101615
pubmed: 37562195
pmcid: 10515285
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5(1):66. https://doi.org/10.1038/s41572-019-0111-2 .
doi: 10.1038/s41572-019-0111-2
pubmed: 31548545
US Food and Drug Administration. Enhertu® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf . Accessed 18 Sept 2023.
European Medicines Agency. Enhertu (trastuzumab deruxtecan): summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf . Accessed 10 May 2023.
Daiichi Sankyo Co. Ltd. Enhertu
Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2019. 2020. https://www.pmda.go.jp/files/000235289.pdf . Accessed 10 May 2023.
AstraZeneca. Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. 2023. https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html . Accessed 29 Nov 2023.
Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023;8(3): 101541. https://doi.org/10.1016/j.esmoop.2023.101541 .
doi: 10.1016/j.esmoop.2023.101541
pubmed: 37178669
pmcid: 10186487
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines
doi: 10.6004/jnccn.2023.0031
pubmed: 37308117
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38(17):1887–96. https://doi.org/10.1200/jco.19.02318 .
doi: 10.1200/jco.19.02318
pubmed: 32058843
pmcid: 7280051
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110–20. https://doi.org/10.1038/s41591-023-02478-2 .
doi: 10.1038/s41591-023-02478-2
pubmed: 37488289
pmcid: 10427426
Hamilton EP, Shapiro CL, Boni V, Martin Jimenez M, Del Conte G, Cortés J, et al. 162O Primary analysis from DS8201-A-U105: a 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer [ESMO abstract]. Ann Oncol. 2022;33(Suppl 3):S196. https://doi.org/10.1016/j.annonc.2022.03.181 .
doi: 10.1016/j.annonc.2022.03.181
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690 .
doi: 10.1056/NEJMoa2203690
pubmed: 35665782
pmcid: 10561652
Modi S, Jacot W, Iwata H, Park YH, Vidal Losada MJ, Li W, et al. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): updated survival results of the randomized, phase III DESTINY-Breast04 study [ESMO abstract]. Ann Oncol. 2023;34(Suppl 2):S334–5. https://doi.org/10.1016/j.annonc.2023.09.553 .
doi: 10.1016/j.annonc.2023.09.553
Xu S, Liu Y, Zhang T, Zheng J, Lin W, Cai J, et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Oncol. 2021;11: 689562. https://doi.org/10.3389/fonc.2021.689562 .
doi: 10.3389/fonc.2021.689562
pubmed: 34094989
pmcid: 8176863
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. https://doi.org/10.1016/s0140-6736(11)60070-6 .
doi: 10.1016/s0140-6736(11)60070-6
pubmed: 21376385
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. https://doi.org/10.1200/jco.2013.52.4892 .
doi: 10.1200/jco.2013.52.4892
pubmed: 25605862
pmcid: 4463422
Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365–76. https://doi.org/10.1200/JCO.22.01002 .
doi: 10.1200/JCO.22.01002
pubmed: 36027558
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022 .
doi: 10.1056/NEJMoa2115022
pubmed: 35320644
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510 .
doi: 10.1056/NEJMoa1914510
pubmed: 31825192
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4): 100554. https://doi.org/10.1016/j.esmoop.2022.100554 .
doi: 10.1016/j.esmoop.2022.100554
pubmed: 35963179
pmcid: 9434416
Baba T, Kusumoto M, Kato T, Kurihara Y, Sasaki S, Oikado K, et al. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan. Int J Clin Oncol. 2023;28(12):1585–96. https://doi.org/10.1007/s10147-023-02414-x .
doi: 10.1007/s10147-023-02414-x
pubmed: 37787866
pmcid: 10687185
Iwasa E, Fujiyoshi Y, Kubota Y, Kimura R, Chandler RE, Taavola H, et al. Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting. Drug Saf. 2020;43(11):1121–31. https://doi.org/10.1007/s40264-020-00968-7 .
doi: 10.1007/s40264-020-00968-7
pubmed: 32617874
pmcid: 7575479